Halozyme Therapeutics (HALO) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

Employees

Data from SEC filings

Employee count

CEO pay ratio

CEO Salary

Median Employee Salary

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Ecosystem Environment Environmental Materials Natural Resources Nature Nuclear Offset Package Packaging Pandemic Raw Materials Water Access African American Asian Attrition Benefits Black Citizenship Community Culture Customer Cyber Security Cybersecurity Data Privacy Death Demographic Disability Diversity Diversity and Inclusion Drug Pricing Employee Employee Engagement Employee Retention Employee Training Engagement Ethnicity Gender Health and Safety Health Care Healthcare Hire Hiring Hispanic Human Capital Human Resources Incident Injured Latinx LGBTQ Minority Perquisites Pulse Survey Recall Recruitment Reimbursement Retention Retirement Safety Satisfaction Sexual Harassment Skill Skilled Skills Social Stakeholder Supplier Supply Chain Talent Training Union Unionized Women Workforce Workplace Safety Activist Assessment Assurance Audit Board Effectiveness Bonus Chronic Class Action Lawsuit Classified Classified Board Claw Back Clawback Commitment Conflict of Interest Corporate Governance Corporate Purpose Enterprise Risk Management ESG Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Innovation Innovative Investigation Key Performance Indicator Lawsuit Leadership Litigation Long-term Majority Mission Oversee Oversight Perquisite Pledging Proxy Contest Purpose Quality Standard R&D Reputation Reputational Research and Development Responsibility Responsible Single Trigger Special Meeting Strategy Sustainability Sustainable Targets Tax Tenure Transparency

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

On May 5, 2022, Halozyme Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders. Of the 137,772,750 shares of the Company's common stock outstanding as of the record date, 127,251,460 shares were represented at the annual meeting.
The stockholders considered three proposals at the meeting, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 25, 2022. The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below.
Proposal 1: Election of three Class III directors to hold office for a three-year term expiring at the 2025 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified:

Names	Votes For	Votes Against	Abstain	Broker Non-Votes

Jeffrey W. Henderson	110,983,960	3,917,902	86,787	12,262,811
Connie L. Matsui	104,769,877	9,727,808	490,964	12,262,811
Helen I. Torley	114,703,295	208,526	76,828	12,262,811

Each of the foregoing candidates were elected and each received affirmative votes from more than a majority of the outstanding shares.
Proposal 2: The advisory vote on the compensation of the Company's named executive officers was as follows:

Votes For						Votes Against						Abstain						Broker Non-Votes

110,559,045						4,295,540						134,064						12,262,811

The foregoing proposal was approved.
Proposal 3: The vote on a proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022 was as follows:

Votes For						Votes Against						Abstain						Broker Non-Votes

126,668,977						510,101						72,382						—

The foregoing proposal was approved.